4,060 results on '"PONIKOWSKI, PIOTR"'
Search Results
2. High-intensity care for GDMT titration
3. Role of dietary sodium restriction in chronic heart failure: systematic review and meta-analysis
4. The role of urine chloride in acute heart failure
5. Effectiveness of remote pulmonary artery pressure estimating in heart failure: systematic review and meta-analysis
6. Author Correction: Spot urine sodium as a marker of urine dilution and decongestive abilities in acute heart failure
7. Spot urine sodium as a marker of urine dilution and decongestive abilities in acute heart failure
8. Urinary Marker Profiles in Heart Failure with Reduced Versus Preserved Ejection Fraction
9. Rapid Uptitration of Guideline-Directed Medical Therapies in Acute Heart Failure With and Without Atrial Fibrillation
10. Vericiguat and Cardiovascular Outcomes in Heart Failure by Baseline Diabetes Status: Insights From the VICTORIA Trial
11. Dapagliflozin and Timing of Prior Heart Failure Hospitalization: A Patient-Level Meta-Analysis of DAPA-HF and DELIVER
12. Association of Reduced Left Atrial Reserve With Exercise Intolerance and Outcome in Hypertension
13. Titration of Medications After Acute Heart Failure Is Safe, Tolerated, and Effective Regardless of Risk
14. Characteristics, treatment, and outcomes of early vs. late enrollees of the STRONG-HF trial
15. Left Ventricular Function, Congestion, and Effect of Empagliflozin on Heart Failure Risk After Myocardial Infarction
16. Intravenous ferric carboxymaltose for iron repletion following acute heart failure in patients with and without diabetes: a subgroup analysis of the randomized AFFIRM-AHF trial
17. Sex-stratified patterns of emergency cardiovascular admissions prior and during the COVID-19 pandemic
18. Sodium–glucose co‐transporter 2 inhibitors as an early, first‐line therapy in patients with heart failure and reduced ejection fraction
19. Iron deficiency in heart failure
20. Heart failure clinical assessment
21. Ancillary procedures
22. Inotropes and inodilators
23. Pathophysiology and Treatment Opportunities of Iron Deficiency in Heart Failure: Is There a Need for Further Trials?
24. Recurrent Hospitalizations and Response to Vericiguat in Heart Failure and Reduced Ejection Fraction
25. Safety Indicators in Patients Receiving High-intensity Care After Hospital Admission for Acute Heart Failure: The STRONG-HF Trial
26. Differential biomarker expression in heart failure patients with and without mitral regurgitation: Insights from BIOSTAT-CHF
27. Heart Failure, Investigator-Reported Sleep Apnea and Dapagliflozin: A Patient-Level Pooled Meta-Analysis of DAPA-HF and DELIVER
28. Impact of Rapid Up-Titration of Guideline-Directed Medical Therapies on Quality of Life: Insights From the STRONG-HF Trial
29. Contribution of reduced skeletal muscle perfusion reserve to exercise intolerance in heart failure with preserved ejection fraction
30. The Effects of Burst Steroid Therapy on Short-term Decongestion in Acute Heart Failure Patients With Pro-inflammatory Activation: A Post Hoc Analysis of the CORTAHF Randomized, Open-label, Pilot Trial
31. Comparing Analytical Methods for Composite End Points in Clinical Trials: Insights from the Vericiguat Global Study in Subjects with Heart Failure With Reduced Ejection Fraction Trial
32. The Effect of Omecamtiv Mecarbil in Hospitalized Patients as Compared With Outpatients With HFrEF: An Analysis of GALACTIC-HF
33. Relationship of Vascular Endothelial Growth Factor C, a Lymphangiogenesis Modulator, With Edema Formation, Congestion and Outcomes in Acute Heart Failure
34. Baseline characteristics of patients in the randomized study to investigate the efficacy and safety of ferric carboxymaltose as treatment for heart failure with iron deficiency: HEART-FID trial
35. Pressure–Volume Profiles in Heart Failure Across Sexes and Phenotypes
36. Hierarchical End Points in Prior Heart Failure Trials and the HEART-FID Trial
37. Global Rounds: Poland
38. Dapagliflozin in Patients With Heart Failure and Deterioration in Renal Function
39. Role of Lymphatics in Heart Failure
40. Vascular Disease Burden, Outcomes and Benefits with Empagliflozin in Heart Failure: Insights From the EMPEROR-Reduced Trial
41. Dapagliflozin and Physical and Social Activity Limitations in Heart Failure With Reduced Ejection Fraction
42. Common mechanistic pathways in cancer and heart failure. A scientific roadmap on behalf of the Translational Research Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC).
43. Efficacy of empagliflozin in heart failure with preserved versus mid-range ejection fraction: a pre-specified analysis of EMPEROR-Preserved
44. Management of Worsening Heart Failure With Reduced Ejection Fraction: JACC Focus Seminar 3/3
45. Effect of Sotagliflozin on Early Mortality and Heart Failure-Related Events: A Post Hoc Analysis of SOLOIST-WHF
46. Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)
47. Cognitive Decline Over Time in Patients With Systolic Heart Failure Insights From WARCEF
48. Hepatorenal dysfunction identifies high‐risk patients with acute heart failure: insights from the RELAX‐AHF trial
49. Minimal Clinically Important Differences in 6-Minute Walk Test in Patients With HFrEF and Iron Deficiency
50. Safety, Feasibility of Controllable Decrease of Vena Cava Pressure by Doraya Catheter in Heart Failure
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.